Liposomal imatinib-mitoxantrone combination: Formulation development and therapeutic evaluation in an animal model of prostate cancer

Prostate

Volumn 71, Issue 1, 2011, Pages 81-90

  Pinto, Ana Catarina ^a,b   Moreira, João Nuno ^a,c   Simões, Sérgio ^a,b,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Bluepharma   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

imatinib; in vivo therapeutic activity; liposomes; mitoxantrone; prostate cancer

Indexed keywords

CHOLESTEROL; DISTEAROYLPHOSPHATIDYLCHOLINE; IMATINIB; LIPOSOME; MITOXANTRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RETENTION; DRUG STABILITY; ENCAPSULATION; HUMAN; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; LIPOSOMES; MALE; MICE; MICE, NUDE; MITOXANTRONE; PIPERAZINES; PROSTATIC NEOPLASMS; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649591508     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21224     Document Type: Article

References (50)

1. Sonpavde G, Hutson TE, Berry WR,. Hormone refractory prostate cancer: Management and advances. Cancer Treat Rev 2006; 32 (2): 90-100. (Pubitemid 43362230)
2. Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS,. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005; 62 (2): 115-122. (Pubitemid 40096777)
3. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12 (6): 1665-1671.
4. So A, Gleave M, Hurtado-Col A, Nelson C,. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005; 23 (1): 1-9.
5. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC,. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14 (6): 1756-1764.
6. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513-1520.
7. Buchdunger E, O'Reilly T, Wood J,. Pharmacology of imatinib (STI571). Eur J Cancer 2002; 38 (Suppl. 5): S28-S36.
8. Ostman A, Heldin CH,. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007; 97: 247-274.
9. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C,. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004; 22 (16): 3323-3329. (Pubitemid 41103689)
10. Hande KR,. Topoisomerase II inhibitors. Update Cancer Ther 2008; 3: 13-26.
11. Wiseman LR, Spencer CM,. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997; 10 (6): 473-485.
12. Cho K, Wang X, Nie S, Chen ZG, Shin DM,. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14 (5): 1310-1316.
13. Lammers T, Hennink WE, Storm G,. Tumour-targeted nanomedicines: Principles and practice. Br J Cancer 2008; 99 (3): 392-397.
14. Devalapally H, Chakilam A, Amiji MM,. Role of nanotechnology in pharmaceutical product development. J Pharm Sci 2007; 96 (10): 2547-2565.
15. Samad A, Sultana Y, Aqil M,. Liposomal drug delivery systems: An update review. Curr Drug Deliv 2007; 4 (4): 297-305.
16. Jantscheff P, Esser N, Graeser R, Ziroli V, Kluth J, Unger C, Massing U,. Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts. Prostate 2009; 69 (11): 1151-1163.
17. Li C, Cui J, Wang C, Li Y, Zhang H, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y,. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm 2008; 70 (2): 657-665.
18. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB,. Liposomal irinotecan: Formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 2004; 10 (19): 6638-6649.
19. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB,. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 2000; 292 (1): 337-345.
20. Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P,. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73 (5): 1478-1484.
21. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K,. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000; 65 (1-2): 271-284.
22. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D,. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51 (4): 691-743.
23. Mayer LD, Hope MJ, Cullis PR,. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 1986; 858 (1): 161-168.
24. Jaeger N, Demeyene H, Finsy R, Sneyens R, Vonderdeelen J, Meeren P, Laethem M,. Particle sizing by photon correlation spectroscopy. Part Part Syst Char 1991; 8 (1-4): 179-186.
25. Haran G, Cohen R, Bar LK, Barenholz Y,. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993; 1151 (2): 201-215.
26. Bolotin EM, Cohen R, Bar LK, Emanuel M, Ninio S, Barenholz Y, Lasic DD,. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligand-liposomes. J Lipos Res 1994; 4 (1): 455-479.
27. Bartlett G,. Phosphorus assay in column chromatography. J Biol Chem 1959; 234: 466-468.
28. Chonn A, Semple SC, Cullis PR,. Separation of large unilamellar liposomes from blood components by a spin column procedure: Towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim Biophys Acta 1991; 1070 (1): 215-222.
29. Tomayko MM, Reynolds CP,. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24 (3): 148-154.
30. Pinto AC, Angelo S, Moreira JN, Simoes S,. Development, characterization and in vitro evaluation of single or co-loaded imatinib mesylate liposomal formulations. 2010 (submitted for publication).
31. Johnston MJ, Semple SC, Klimuk SK, Edwards K, Eisenhardt ML, Leng EC, Karlsson G, Yanko D, Cullis PR,. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 2006; 1758 (1): 55-64.
32. Van Laar ES, Weitman S, MacDonald JR, Waters SJ,. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate 2004; 59 (1): 22-32.
33. Pinto AC, Angelo S, Moreira JN, Simoes S,. Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy. Cancer Chemother Pharmacol Published on-line on 9th April 2010. DOI: 10.1007/s00280-010-1315-z.
34. Le Tourneau C, Faivre S, Raymond E,. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 2008; 34 (1): 37-48.
35. Suggitt M, Bibby MC,. 50 years of preclinical anticancer drug screening: Empirical to target-driven approaches. Clin Cancer Res 2005; 11 (3): 971-981.
36. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ,. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 2006; 98 (11): 783-793.
37. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ,. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003; 95 (6): 458-470.
38. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K,. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61 (7): 2929-2934.
39. Pietras K,. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 2004; 31 (2 Suppl. 6): 18-23.
40. Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, Vujaskovic Z, Dewhirst MW,. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 2007; 97 (6): 735-740.
41. Lim HJ, Masin D, Madden TD, Bally MB,. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 1997; 281 (1): 566-573.
42. Gokhale PC, Pei J, Zhang C, Ahmad I, Rahman A, Kasid U,. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Anticancer Res 2001; 21 (5): 3313-3321.
43. Peng B, Lloyd P, Schran H,. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44 (9): 879-894.
44. Czejka MJ, Jager W, Georgopoulos A, Schuller J,. Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. Eur J Drug Metab Pharmacokinet 1990; 15 (3): 219-222.
45. Bastide C, Bagnis C, Mannoni P, Hassoun J, Bladou F,. A Nod Scid mouse model to study human prostate cancer. Prostate Cancer Prostatic Dis 2002; 5 (4): 311-315.
46. An Z, Wang X, Geller J, Moossa AR, Hoffman RM,. Surgical orthotopic implantation allows high lung and lymph node metastatic expression of human prostate carcinoma cell line PC-3 in nude mice. Prostate 1998; 34 (3): 169-174.
47. Fridman R, Kibbey MC, Royce LS, Zain M, Sweeney M, Jicha DL, Yannelli JR, Martin GR, Kleinman HK,. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. J Natl Cancer Inst 1991; 83 (11): 769-774.
48. El Hilali N, Rubio N, Blanco J,. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase. Clin Cancer Res 2005; 11 (3): 1253-1258.
49. Sanchez AM, Sanchez MG, Malagarie-Cazenave S, Olea N, Diaz-Laviada I,. Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin. Apoptosis 2006; 11 (1): 89-99.
50. Euhus DM, Hudd C, LaRegina MC, Johnson FE,. Tumor measurement in the nude mouse. J Surg Oncol 1986; 31 (4): 229-234.